5. 進行性核上性麻痺 Progressive supranuclear palsy Clinical trials / Disease details


臨床試験数 : 89 薬物数 : 107 - (DrugBank : 40) / 標的遺伝子数 : 65 - 標的パスウェイ数 : 108

  
3 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2009-013097-40-ES
(EUCTR)
17/11/200929/07/2009Estudio doble-ciego, controlado con placebo, aleatorizado, de grupos paralelos, para evaluar la seguridad, tolerancia y eficacia de dos dosis orales diferentes de NP031112, un inhibidor de GSK3, versus placebo, como tratamiento de pacientes con Parálisis Supranuclear Progresiva leve o moderadaEstudio doble-ciego, controlado con placebo, aleatorizado, de grupos paralelos, para evaluar la seguridad, tolerancia y eficacia de dos dosis orales diferentes de NP031112, un inhibidor de GSK3, versus placebo, como tratamiento de pacientes con Parálisis Supranuclear Progresiva leve o moderada Parálisis Supranuclear Progresiva leve o moderada
MedDRA version: 9;Level: LLT;Classification code 10036813;Term: Progressive supranuclear palsy
MedDRA version: 9;Level: PT;Term: Progressive supranuclear palsy
Product Name: NP031112
Product Code: NP031112 600mg
Other descriptive name: 4-benzyl-2-naphtalen-1-yl-1,2,4-thiadiazolidine-3,5-dione
Product Name: NP031112
Product Code: NP031112 800mg
Other descriptive name: 4-benzyl-2-naphtalen-1-yl-1,2,4-thiadiazolidine-3,5-dione
Noscira S.A.NULLNot RecruitingFemale: yes
Male: yes
125Spain;Germany;United Kingdom
2EUCTR2009-013097-40-DE
(EUCTR)
06/11/200930/07/2009A double-blind, placebo-controlled, randomized, parallel-group study evaluating thesafety, tolerability and efficacy of two different oral doses of NP031112, a GSK-3inhibitor, versus placebo in the treatment of patients with mild to moderateProgressive Supranuclear Palsy. - TAUROSA double-blind, placebo-controlled, randomized, parallel-group study evaluating thesafety, tolerability and efficacy of two different oral doses of NP031112, a GSK-3inhibitor, versus placebo in the treatment of patients with mild to moderateProgressive Supranuclear Palsy. - TAUROS Mild to Moderate Progressive Supranuclear Palsy
MedDRA version: 12.0;Level: LLT;Classification code 10036813;Term: Progressive supranuclear palsy
MedDRA version: 12.0;Level: PT;Term: Progressive supranuclear palsy
Product Name: NP031112
Product Code: NP031112 600mg
Other descriptive name: 4-benzyl-2-naphtalen-1-yl-1,2,4-thiadiazolidine-3,5-dione
Product Name: NP031112
Product Code: NP031112 800mg
Other descriptive name: 4-benzyl-2-naphtalen-1-yl-1,2,4-thiadiazolidine-3,5-dione
Noscira S.A.NULLNot RecruitingFemale: yes
Male: yes
125United Kingdom;Spain;Germany
3EUCTR2009-013097-40-GB
(EUCTR)
30/10/200923/07/2009 A double-blind, placebo-controlled, randomized, parallel-group study evaluating the safety, tolerability and efficacy of two different oral doses of NP031112, a GSK-3 inhibitor, versus placebo in the treatment of patients with mild to moderate Progressive Supranuclear Palsy. - TAUROS A double-blind, placebo-controlled, randomized, parallel-group study evaluating the safety, tolerability and efficacy of two different oral doses of NP031112, a GSK-3 inhibitor, versus placebo in the treatment of patients with mild to moderate Progressive Supranuclear Palsy. - TAUROS Mild to Moderate Progressive Supranuclear Palsy
MedDRA version: 12.0;Level: LLT;Classification code 10036813;Term: Progressive supranuclear palsy
MedDRA version: 12.0;Level: PT;Term: Progressive supranuclear palsy
Product Name: NP031112
Product Code: NP031112 600mg
Other descriptive name: 4-benzyl-2-naphtalen-1-yl-1,2,4-thiadiazolidine-3,5-dione
Product Name: NP031112
Product Code: NP031112 800mg
Other descriptive name: 4-benzyl-2-naphtalen-1-yl-1,2,4-thiadiazolidine-3,5-dione
Noscira S.A.NULLNot Recruiting Female: yes
Male: yes
140 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): noSpain;Germany;United Kingdom